By Chase Doyle
San Francisco—A retrospective chart review supports mexiletine as an adjuvant therapy for chronic neuropathic pain. According to the data, when used as a second adjunct therapy to anticonvulsants, mexiletine demonstrated improved patient-reported pain and Patient Health Questionnaire-9 (PHQ-9) scores as well as lower daily opioid consumption.
“We were very pleased with the results,” said Kurt Adam Lundberg, DO, an anesthesiologist in the Henry Ford Health